Pretreatment with TNF inhibitors may improve outcomes of combination cancer immunotherapy
Published on: Thursday 02 May 2019
This study proposes a new therapeutic approach against cancer that dissociates efficacy and toxicity in the use of combined immunotherapy in animal models. This clinical strategy consists of blocking TNF protein while applying combination immunotherapy treatment (inhibition therapy of PD-1 and CTLA-4, other proteins that 'slow down' the immune response). Nature, the leading international weekly journal of science, publishes this research in its latest issue.
